Cargando…
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
OBJECTIVES: To assess the neurobiological substrate of initial cognitive decline in Parkinson’s disease (PD) to inform patient management, clinical trial design, and development of treatments. METHODS: We longitudinally assessed, up to 3 years, 423 newly diagnosed patients with idiopathic PD, untrea...
Autores principales: | Caspell-Garcia, Chelsea, Simuni, Tanya, Tosun-Turgut, Duygu, Wu, I-Wei, Zhang, Yu, Nalls, Mike, Singleton, Andrew, Shaw, Leslie A., Kang, Ju-Hee, Trojanowski, John Q., Siderowf, Andrew, Coffey, Christopher, Lasch, Shirley, Aarsland, Dag, Burn, David, Chahine, Lana M., Espay, Alberto J., Foster, Eric D., Hawkins, Keith A., Litvan, Irene, Richard, Irene, Weintraub, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435130/ https://www.ncbi.nlm.nih.gov/pubmed/28520803 http://dx.doi.org/10.1371/journal.pone.0175674 |
Ejemplares similares
-
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018) -
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020) -
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018) -
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018) -
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)